James Cullem - Paradigm Oncology Overview

PARADIGM ONCOLOGY (Danvers, MA) is a start-up cancer diagnostics company dedicated to Bringing the Promise of Personalized Medicine to Glioblastoma multiforme (GBM) patients. We are developing a first-in-class and first-in-kind, GBM-specific tumor-profiling test to help inform treatment options and decision-making for GBM patients and their treating neuro-oncologists. Our predictive diagnostic test, based in part on a pair of novel biomarkers that we have exclusively licensed, will be offered to patients and their physician at the time of GBM diagnosis and prior to chemotherapy, in order to provide valuable information about the molecular mechanisms of that patients particular tumor as early as possible, to help guide subsequent patient care. Our experienced leadership team is complimented by a world-class advisory board, including some of the most respected GBM experts at the forefront of our understanding of GBM tumor biology and therapy.